Clinical significance of interstitial lung abnormalities and immune checkpoint <scp>inhibitor‐induced</scp> interstitial lung disease in patients with <scp>non‐small</scp> cell lung cancer

Abstract

The presence of nonfibrotic ILAs is a significant risk for early-onset ICI-ILD in patients with NSCLC undergoing ICI monotherapy. Clinicians should be aware of ILAs, especially nonfibrotic ILAs, before administering ICIs to lung cancer patients.